NFKB1 and congenital rubella syndrome: Consistently, in vitro studies confirmed that the nanozyme inhibited the phosphorylation of Syk and its downstream effector NF-κB, thereby reducing pro-inflammatory cytokine levels.<h4>Conclusion</h4>Our findings demonstrate that this ROS-responsive nanozyme provides a novel and effective therapeutic strategy for CRS in preclinical models, warranting further pharmacokinetic and toxicological evaluation to support clinical translation.